Results 51 to 60 of about 822 (144)

Nonalcoholic fatty liver disease: New epidemic

APIK Journal of Internal Medicine, 2021
The global obesity epidemic has dramatically increased the prevalence of nonalcoholic fatty liver disease (NAFLD), such that it is the most common cause of chronic liver disease in Western nations.
Rajkumar P Wadhwa, Deven Shrikant Gosavi, Aathira Ravindranath   +2 more
doaj   +1 more source

Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis

Hepatology Communications, 2022
Dysregulated hepatocyte lipid metabolism is a hallmark of hepatic lipotoxicity and contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH).
Archana Vijayakumar, Ayse Okesli‐Armlovich, Ting Wang, Isabel Olson, Minji Seung, Saritha Kusam, David Hollenback, Sangeetha Mahadevan, Bruno Marchand, Maria Toteva, David G. Breckenridge, James L. Trevaskis, Jamie Bates   +12 more
doaj   +1 more source

Comparative Efficacy of Saroglitazar and Pioglitazone in Nonalcoholic Fatty Liver Disease Patients: A Bayesian Network Meta-analysis

International Journal of Diabetes and Technology
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome. Two drugs, saroglitazar (S) and pioglitazone (P), are known to have beneficial effects on metabolic syndrome.
Binayak Sinha, Samit Ghosal, Debasis Datta   +2 more
doaj   +1 more source

The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies

Indian Heart Journal, 2013
Diabetes mellitus (DM) is a pandemic disease and an important cardiovascular (CV) risk factor. The atherogenic dyslipidemia in diabetes (ADD) is characterized by high serum triglycerides, high small dense LDL levels, low HDL levels and postprandial ...
P.C. Manoria, H.K. Chopra, S.K. Parashar, A.L. Dutta, Brian Pinto, Ajit Mullasari, Samir Prajapati   +6 more
doaj   +1 more source

The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents

Frontiers in Gastroenterology
BackgroundMetabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH), is a progressive liver disease and a leading cause of cirrhosis and liver-related mortality worldwide, affecting approximately 3%–5% of the ...
Abeer Qasim, Rayan Alataa, Fnu Veena, Elona Shehi   +3 more
doaj   +1 more source

Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease

Biomedicines
Three peroxisome proliferator-activated receptor subtypes, PPARα, PPAR(ß/)δ, and PPARγ, exert ligand-dependent transcriptional control in concert with retinoid X receptors (RXRs) on various gene sets harboring PPAR response elements (PPREs) in their ...
Shotaro Kamata, Akihiro Honda, Nonoka Kashiwagi, Ayumi Shimamura, Sayaka Yashiro, Yuna Komori, Aoi Hosoda, Noriyuki Akahoshi, Isao Ishii   +8 more
doaj   +1 more source

Saroglitazar's Therapeutic Use in Metabolic Syndrome and Nafld

Background: Saroglitazar is a novel anti-diabetic drug with combined PPAR-α/-γ agonistic activity. It was developed domestically by an Indian company called Zydus Cadila in 2001, and after numerous preclinical and clinical trials, it received regulatory approval from the Indian drug controller and regulatory authority called DCGI, India in June 2013 ...
openaire   +1 more source

Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia

Heart Research - Open Journal, 2017
Vineet Bhatia, Parneesh Arora, Gagandeep Kaur, Upendera Kaul   +3 more
openaire   +1 more source

Saroglitazar: One Molecule for Managing Two Diseases, Type 2 Diabetes and Hypertriglyceridemia

Clinical Diabetology, 2022
Dhruvi Hasnani, Vipul Chavda
doaj   +1 more source

Saroglitazar: The revolution in India

Journal of Indian College of Cardiology, 2016
openaire   +1 more source